Posted by Michael Wonder on 06 Sep 2023
Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy
6 September 2023 - NICE has published final evidence-based recommendations on the use of mavacamten (Camzyos) for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy.
Mavacamten is recommended as an option for treating symptomatic obstructive hypertrophic cardiomyopathy in adults who have a New York Heart Association class of 2 to 3. It is recommended only if it is an add‑on to individually optimised standard care that includes beta‑blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contra-indicated.
